Initiation of a phase 2 trial of RP101 in latestage pancreatic cancer patients
12-Feb-2008 -
RESprotect´s US development partner, SciClone Pharmaceuticals, Inc. announced that the first patient has been dosed in its phase 2 clinical trial using RP101, a nucleoside analog which may act to enhance the beneficial effect of chemotherapy, for the treatment of pancreatic cancer.
RESprotect, ...
breast cancer
chemotherapy
cisplatin
+4